-
Postdoc in CRISPR Meta-Analytics and AI for Therapeutic Target Discovery and Priotisation (OT Grant)
(obtained at the call closure time or near completion) in a relevant subject, e.g., bioinformatics, computer science, mathematics, physics, engineering or a related field of science. Proven track record
-
. We utilize a multifaceted approach that encompasses preclinical studies in immune competent syngeneic and genetically engineered co-mutational models of KRAS - mutant NSCLC as well as PDX/CDXs, in
-
assays for functional screens to dissect GPCR signaling Using fluorescence and FRET/BRET-based reporters of GPCR signaling and ligand binding Engineering mammalian cell lines and molecular cloning Cell and
-
, Physics, Engineering, or a related field • Prior experience in modeling viral infections, bacterial infections, and/or immune response dynamics • Experience with parameter estimation techniques and data
-
of rare disease funded by the National Human Genome Research Institute (NHGRI) and as a sequence technology core for the Texas Medical Center Genomic Center for Infectious Disease (GCID) established by
-
molecular biology and immunology techniques along with multi-omics approaches, including sc-RNA-seq, bulk RNAseq, epigenomics, metabolomics, proteomics, CRISPR screens and genetically engineered mouse models
-
gain new insights into biological concepts and disease targets. We will combine advanced cellular and molecular techniques in immunology and neurobiology with genetic-engineering tools, quantitative
-
cancer progression. We employ a diverse array of pre-clinical models including cancer cell lines, 3D spheroid cultures, orthotopic xenografts, patient-derived xenografts (PDXs), and genetically engineered
-
or vaccination outcomes to identify an immunological signature associated with protective viral immunity. Responsibilities: Lead a project on developing a novel AI platform engineered and utilized the platform
-
, and animal models preferred. The lab leverages genetically engineered mouse models, patient-derived xenografts, human and mouse tumor and primary cell lines as well as induced pluripotent stem cells as